When administered prior to stroke, C21 significantly attenuated the loss of neurons in the ischemic tissue, such that the number of NeuN-positive cells in the infarcted region was comparable to the number of NeuN-positive cells in the unaffected area (153.10±17.23; 181.50±14.48 NeuN-positive cells per mm2 respectively. This evidence concerns the gene RBFOX3 and stroke disorder.